OPKO Health amends note agreement, issues $125 million in additional senior secured notes
The notes, tied to EirGen Pharma's mazdutide royalty interest from Eli Lilly, mature in 2044 and carry a SOFR-plus-7.5% rate with a 4% floor.
SEC filing
Latest
3 stories
Friday, August 14
Monday, August 3
Cocrystal Pharma confirms $5 million OPKO Health private placement in 8-K filing
The filing details the July 31, 2026 stock sale to longtime investor OPKO as Cocrystal's norovirus drug CDI-988 nears Phase 1b topline data.
SEC filing
Monday, July 27
OPKO reports Q2 2026 results with multiple pipeline milestones across ModeX and OPKO Biologics
OPKO detailed new trial starts for MDX2003 and MDX2301, upcoming Phase 1 plans for its in vivo CAR T programs, and an expanded Rayaldee deal in China.
SEC filing